Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients

Thrombosis Research

Volumn 125, Issue 2, 2010, Pages

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

biochemical profile; cardiovascular disease; haemostasis; kynurenines; peritoneal dialysis

Indexed keywords

ALBUMIN; ANTIPLASMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KYNURENIC ACID; KYNURENINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; QUINOLINIC ACID; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TRYPTOPHAN; UROKINASE; UROKINASE RECEPTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DEGRADATION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIFIBRINOLYTIC AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; FIBRINOLYSIN; HEMOSTASIS; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLAND; PREVALENCE; PROTHROMBIN; QUINOLINIC ACID; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THROMBOPLASTIN; TRYPTOPHAN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 76449091049     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.08.009     Document Type: Article

References (27)

1. Prichard S. Cardiovascular risk in peritoneal dialysis. Contrib Nephrol 140 (2003) 82-90
2. Lameire N., Bernaert P., Lambert M.-C., and Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 46 Suppl 48 (1994) S31-S38
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
4. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
5. Rosenberg R.D., and Bauer K.A. Prothrombin activation fragment assay. Clin Chem 39 (1993) 559-560
6. Morange P.E., Bickel C., Nicaud V., Schnabel R., Rupprecht H.J., Peetz D., et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease. The AtheroGene Study. Arterioscler Thromb Vasc Biol 26 (2006) 2793-2799
7. Sakkinen P.A., Cushman M., Psaty B.M., Rodriguez B., Boineau R., Kuller L.H., et al. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and momen. Arterioscler Thromb Vasc Biol 19 (1999) 499-504
8. Lijnen H.R., and Collen D. Mechanisms of physiological fibrinolysis. Bailliere's Clinical Hematology vol. 8 (1995), Bailliera Tindall, London, UK 277-290
9. Levi M., de Boer J.P., Roem D., ten Cate J.W., and Hack C.E. Plasminogen activation in vivo upon intravenous infusion of DDAVP: quantitative assessment of plasmin-α2-antiplasmin complexes with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 67 (1992) 111-116
10. Vassalli J.-D., Baccino D., and Belin D. A cellular binding-site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100 (1985) 86-92
11. Schroecksnadel K., Frick B., Winkler C., and Fusch D. Crucial role of interferon-γ and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 4 (2006) 205-213
12. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45 (1993) 309-379
13. Pawlak K., Domaniewski T., Mysliwiec M., and Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204 (2009) 309-314
14. Pawlak K., Brzosko S., Mysliwiec M., and Pawlak D. Kynurenine, quinolinic acid - The new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 204 (2009) 561-566
15. Babazono T., Miyamae M., Tomonaga O., and Omori Y. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 12 (1996) 120-125
16. Preloznik Zupan I., Sabovic M., Salobir B., and Buturovic Ponikvar J. Characterization of the pro-thrombotic state In CAPD patients. Ren Fail 30 (2008) 597-602
17. Oda H., Ohno M., and Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial 16 (2000) 152-155
18. Tomura S., Nakamura Y., Mayumi D., Ando R., Ida T., Chida Y., et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipids as a cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 27 (1996) 848-854
19. Pawlak D., Tankiewicz A., Mysliwiec P., and Buczko W. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 90 (2002) 328-335
20. Haddock R.C., Spell M.L., Baker III C.D., Grammer J.R., Parks J.M., et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem 266 (1991) 21446-21473
21. Reuning U., and Bang N.U. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. Arterioscler Thromb 12 (1992) 1161-1170
22. Nykjaer A., Petersen C.M., Christensen E.I., Davisen O., and Gliemann J. Urokinase receptors in human monocytes. Biochim Biophys Acta 1052 (1990) 399-407
23. Gyöngyösi M., Glogar D., Weidinger F., Domanovits H., Laggner A., Wojta J., et al. Association between plasmin activation system and intravascular ultrasound signs of plaqe instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 147 (2004) 158-164
24. Cavagna R., Schiavon R., Tessarin C., Papa N., Scorrano D., Casol D., et al. Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13 Suppl. 2 (1993) 402-405
25. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., and Albuquerque E.X. The brain metabolite kynurenic acid metabolite inhibits alpha 7 nicotinic receptor activity and increases non-alpha 7 nicotinic receptor expression: physiopathological implications. J Neurosci 21 (2001) 7463-7473
26. Wessler J., Kirkpatrick C.J., and Racke K. Non-neuronal acetylocholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 77 (1998) 59-79
27. Wejksza K., Rzeski W., Parada-Turska J., Zdzisinska B., Rejdak R., Kocki T., et al. Kynurenic acid production in cultured bosine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn-Schmiedeberg's Arch Pharmacol 369 (2004) 300-304